ASX Share rice
Sun 09 Aug 2020 - 01:18:am (Sydney)

CDY Share Price

CELLMID LIMITEDCDYPharmaceuticals, Biotechnology & Life Sciences

CDY Company Information

Name:

Cellmid Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

55 Clarence Street Sydney NSW Australia 2000

Phone:

61 2 9221 6830

CEO, MD & Exec. Director:

Ms. Maria Halasz

Chief Exec. Officer of Lyramid Limited:

Dr. Bart Wuurman

Managing Director of Advangen Inc:

Mr. Koichiro Koike

Chief Operating Officer:

Mr. Dominic Burg

Head of R&D:

Dr. Graham Robertson

Company Overview:

Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool. It is also developing CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. In addition, the company develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.

CDY Share Price Information

Shares Issued:

96.60M

Market Capitalisation:

$11.59M

Revenue (TTM):

$7.65M

Revenue Per Share (TTM):

$0.09

Earnings per Share:

$-0.078

Profit Margin:

-0.4966

Operating Margin (TTM):

$-0.15

Return On Assets (TTM):

$-0.06

Return On Equity (TTM):

$-0.51

Quarterly Revenue Growth (YOY):

0.055

Gross Profit(TTM):

$5.32M

Diluted Earnings Per Share (TTM):

$-0.046

CDY CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-65,677

Change To Liabilities:

$1.18M

Total Cashflow From Investing Activities:

$-65,677

Net Borrowings:

$-1,987,446

Net Income:

$-5,909,557

Total Cash From Operating Activities:

$-5,671,373

Depreciation:

$152.89K

Change To Inventory:

$-355,368

Change To Account Receivables:

$-1,255,325

Sale Purchase Of Stock:

$-585,294

Capital Expenditures:

$65.68K

CDY Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-5,885,445

Net Income:

$-5,909,557

Gross Profit:

$5.16M

Operating Income:

$-6,695,900

Other Operating Expenses:

$502.18K

Interest Expense:

$235.04K

Income Tax Expense:

$24.11K

Total Revenue:

$7.30M

Total Operating Expenses:

$11.86M

Cost Of Revenue:

$2.14M

CDY Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$1.76M

Total Liabilities:

$3.93M

Total Stockholder Equity:

$5.86M

Other Current Liabilities:

$1.74M

Total Assets:

$9.79M

Common Stock:

$47.77M

Other Current Assets:

$246.62K

Retained Earnings:

$-42,540,913

Other Liabilities:

$6.74K

Cash:

$3.08M

Total Current Liabilities:

$2.91M

Short-Term Debt:

$266.80K

Property - Plant & Equipment:

$800.24K

Net Tangible Assets:

$4.10M

Total Current Assets:

$7.23M

Long-Term Debt:

$1.02M

Net Receivables:

$2.23M

Short-Term Investments:

$2.56M

Inventory:

$1.62M

Accounts Payable:

$685.22K

Non Currrent Assets (Other):

$2.56M

Short-Term Investments:

$2.56

Non Current Liabilities Total:

$1.03M

CDY Share Price History

CDY News

02 Apr, 2020
Maria Halasz became the CEO of Cellmid Limited (ASX:CDY) in 2007. This analysis aims first to contrast CEO...
03 Feb, 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
04 Dec, 2019
Cellmid Limited (ASX:CDY) shareholders should be happy to see the share price up 24% in the last month. But don't envy...